InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. In pulmonology, Co. is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), an irreversible, unpredictable and fatal lung disease. Pirfenidone is an orally active, small molecule compound that has been developed for the treatment of IPF. Pirfenidone is sold in Germany under the trade name Esbriet, and Esbriet is also commercially available in various European countries, including main markets such as France, Italy and the U.K. Co. is also pursuing the registration of pirfenidone to treat IPF in the U.S.

ITMN — News

ITMN — Price Chart